Experimental virus-antibody combo tested for tough skin cancers
NCT ID NCT04163952
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a combination of two drugs—a virus-based therapy (talimogene laherparepvec) and an antibody (panitumumab)—in 5 people with advanced skin squamous cell carcinoma that had spread or come back. The main goals were to check safety and see if tumors shrank. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED SKIN SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University Medical Center - Duke Cancer Center
Durham, North Carolina, 27710, United States
-
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York, 10016, United States
-
NYU Langone Medical Center (Tisch Hospital)
New York, New York, 10016, United States
-
New York University Langone Medical Center
New York, New York, 10016, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy aims to shrink inoperable skin cancers
- Can a smaller dose of this cancer drug still work? new trial aims to find out
- Custom-Made cancer vaccine shows promise in advanced tumors
- Rare cancer hope: immune drug shows promise in phase 2 trial
- New combo therapy targets tough skin cancers
- Immunotherapy before surgery shows promise for tough skin cancers